ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 17 of 60
JMBS 2019, 4(6): 119–124
Clinical Medicine

Influence of Demographic Indicators and Concomitant Pathology on the Level of New Biomarkers of Inflammation of GDF–15, P–Selectin and Galectin–3 in Patients with Hypertension in Combination with Type 2 Diabetes

Bilchenko A. O.

The purpose of the study was to assess the impact of demographic indicators and comorbidity on the level of new biomarkers of inflammation of GDF–15, P–selectin and Galectin–3 in blood plasma in patients with hypertension in combination with type 2 diabetes. Material and methods. The study included 121 patients, including 59 women and 62 men aged from 40 to 87 years (mean age 64.7±10.6 years). We determined the levels of new biomarkers of inflammation: growth factor differentiation 15 (GDF–15), P–selectin, Galectin–3, and a reference marker of systemic inflammation, high–sensitive CRP (hs–CRP) using standard sets of reagents, in patients included in the study. Results and discussion. In subgroups of men and women patients with hypertension and type 2 diabetes revealed an unreliable tendency to a higher level of GDF–15 in women compared to men (3163.87±2384.37; 2726.14±1402.79 pg/ml p >0.05, respectively). The level of P–selectin in the subgroup of women did not differ from men, and the level of Galectin–3 was not significantly higher in the subgroup of women compared to the subgroup of men. The level of GDF–15 increased significantly in patients older than 70 years (3886.37±2363.59; 2433.39±1377.56 and 1991.46±1895.53 pg/ml; p <0.05, respectively) compared with younger patients, the level of Galectin–3 was also significantly higher in patients older than 70 years compared with patients up to 50 years. The validity of the difference between the GDF–15 levels in the comparison age groups is also confirmed by the ANOVA. There was an unreliable tendency to increase the level of P–selectin and Galectin–3 in patients who suffered myocardial infarction before in the absence of difference in the level of GDF–15. The absence of reliable correlation of levels of inflammation biomarkers with myocardial infarction testified to the data of correlation analysis, which did not reveal reliable correlation links of any of the inflammation biomarkers with myocardial infarction. P–selectin plasma levels were significantly lower in patients with concomitant atrial fibrillation than in patients with sinus rhythm (76.69±26.44 and 115.77±39.46 pg/ml, p <0.05, respectively). However, the presence of concomitant atrial fibrillation did not significantly affect the level of other biomarkers. Conclusion. The sex of the patients had the same effect: the levels of all biomarkers in the plasma were significantly higher in women than in men. If the level of R–selectin tended to decrease with age, then levels of Galectin–3 and GDF–15 increased significantly in patients older than 70 years. Myocardial infarction did not affect the levels of GDF–15, P–selectin and Galectin–3 in patients with hypertension and type 2 diabetes. Administration of oral anticoagulants led to a decrease in the level of P–selectin in patients with concomitant atrial fibrillation.

Keywords: systemic inflammation, cardiovascular risk, demographic characteristics, concomitant pathology

Full text: PDF (Ukr) 289K

  1. Moriya J. Critical roles of inflammation in atherosclerosis. J Cardiol. 2019 Jan; 73(1): 22–7.
  2. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21; 377(12): 1119–31.
  3. Santos HO, Kones R, Rumana U, Earnest CP, Luiz FMI. Macedo RCO. Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies. Clin Ther. 2019 Jul 13. pii: S0149–2918(19)30298–X
  4. Krintus M, Kozinski M, Kubica J, Sypniewska G. Critical appraisal of inflammatory markers in cardiovascular risk stratification. Crit Rev Clin Lab Sci. 2014 Oct; 51(5): 263–79.
  5. Tzikas S, Vassilikos V, Keller T. GDF–15 as a risk stratification biomarker for cardiovascular disease. Int J Cardiol. 2019 Oct 1; 292: 246–7.
  6. Wang J, Wei L, Yang X, Zhong J. Roles of Growth Differentiation Factor 15 in Atherosclerosis and Coronary Artery Disease. J Am Heart Assoc. 2019 Sep 3; 8(17): e012826.
  7. Korporaal SJA, Molenaar TJM, Lutters BCH, Meurs I, Drost–Verhoef S, Kuiper J, et al. Peptide Antagonists for P–selectin Discriminate between Sulfatide–Dependent Platelet Aggregation and PSGL–1–Mediated Cell Adhesion. J Clin Med. 2019 Aug 20; 8(8); pii: E1266.
  8. Nishikawa H, Nakano F, Liu L, Nakatsuka Y, Okada T, Shiba M, et al. The Role of Galectin–3 in Subarachnoid Hemorrhage: A Preliminary Study. Acta Neurochir Suppl. 2020; 127: 65–8.–3–030–04615–6_11
  9. Wollert KC, Kempf T, Wallentin L. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem. 2017 Jan; 63(1): 140–51.
  10. Emmerson PJ, Duffin KL, Chintharlapalli S, Wu X. GDF15 and Growth Control. Front Physiol. 2018 Nov 27; 9: 1712.
  11. Tanaka T, Biancotto A, Moaddel R, Moore AZ, Gonzalez–Freire M, Aon MA, et al. Plasma proteomic signature of age in healthy humans. Aging Cell. 2018 Oct; 17(5): e12799.
  12. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens. 2018 Dec; 36(12): 2284–309.
  13. Standards of Medical Care in Diabetes 2017. Diabetes Care. 2017 Jan; 40(1): 54–5. 10.2337/dc17–S003
  14. Keng BMH, Gao F, Ewe SH, et al. Galectin–3 as a candidate upstream biomarker for quantifying risks of myocardial ageing. ESC Heart Fail. 2019 Aug 8.
  15. Tentzeris I, Farhan S, Freynhofer MK, Rohla M, Jarai R, Vogel B, et al. Usefulness of Elevated Levels of Growth Differentiation Factor–15 to Classify Patients With Acute Coronary Syndrome Having Percutaneous Coronary Intervention Who Would Benefit from High–Dose Statin Therapy. Am J Cardiol. 2017 Sep 1; 120(5): 747–52.ю
  16. Goenka L, Jha D, Sharma M, Dhandapani VE, George M. Factors which influence the levels of ST–2, Galectin–3 and MMP–9 in Acute Coronary Syndrome. Cardiovasc Hematol Disord Drug Targets. 2019 Jul 18.
  17. Riva N, Vella K, Hickey K, Bertù L, Zammit D, Spiteri S, et al. Biomarkers for the diagnosis of venous thromboembolism: D–dimer, thrombin generation, procoagulant phospholipid and soluble P–selectin. J Clin Pathol. 2018 Nov; 71(11): 1015–22.–2018–205293